A recently published amendment to this standard brings critical updates that manufacturers must integrate to stay compliant and continue to benefit from the standard's extensive advantages.
BS EN ISO 15223-1 Medical devices. Symbols to be used with information to be supplied by the manufacturer - General requirements is a widely recognized standard that specifies the symbols used to convey important information related to medical devices.
These symbols are crucial for manufacturers, healthcare professionals, and end-users, particularly in regions with specific language requirements. The symbols standardize how information is presented on medical devices, their packaging, and accompanying documentation, making it easier for users to understand essential details regardless of their language or location.
This standard is not only about compliance; it’s about enhancing safety, usability, and the efficiency of communication across the global medical device market. Whether used in clinical settings, integrated into regulatory documentation, or applied in quality management systems, the symbols in BS EN ISO 15223-1 support a broad spectrum of industry needs.
To discover more about how standards can help facilitate bringing safe and compliant medical devices to the global market, visit our medical devices topic page.
The newly published amendment to BS EN ISO 15223-1:2021+A1:2025 introduces two significant changes that manufacturers need to incorporate:
Introduction of a defined term for “Authorized Representative”: the amendment adds a new, clearly defined term for an "authorized representative," which is particularly important for manufacturers operating in regions that require the appointment of such representatives. This addition ensures that the term is universally understood and applied consistently across different jurisdictions.
Modification of the EC REP symbol: the amendment modifies the existing EC REP symbol, which previously indicated a European Commission representative. The updated symbol is now more generic, making it applicable in any country or region that mandates the use of an authorized representative. This change is particularly beneficial for manufacturers who distribute their products globally, as it simplifies labelling requirements and reduces the need to create region-specific symbols.
For manufacturers who have previously purchased and implemented BS EN ISO 15223-1, understanding the significance of this amendment is crucial. The standard is a key component of regulatory compliance, particularly in regions like the European Union, where it aligns with the Medical Device Regulation (EU MDR) and In Vitro Diagnostic Regulation (EU IVDR). By adopting the amended version - BS EN ISO 15223-1:2021+A1:2025 - manufacturers ensure that their labelling practices remain compliant with current regulations, avoiding potential legal and regulatory challenges.
Moreover, the amendment reflects a broader global push towards standardization in medical device labelling. As supply chains become increasingly international, the need for symbols that are universally recognized and understood is more important than ever. The recent updates directly address this need, providing symbols that are not only compliant with the latest regulations but also versatile enough to be used across various jurisdictions.
BS EN ISO 15223-1:2021+A1:2025 offers a multitude of benefits that extend beyond regulatory compliance. Here’s why this standard remains invaluable to the medical device industry:
Global standardization: recognized worldwide, these symbols facilitate international regulatory compliance and market access.
Enhanced safety and usability: clear symbols reduce errors and enhance patient safety by conveying critical information effectively across languages.
Regulatory compliance: aligns with major regulations (EU MDR, IVDR, US FDA), streamlining market entry and approval.
Efficiency in communication: overcomes language barriers, reducing costs associated with multiple labels.
Quality management integration: supports consistent labelling, aligning with BS EN ISO 13485 for quality compliance.
Cost and time savings: standardized symbols lower production costs and streamline packaging design, freeing up label space.
If you have already invested in BS EN ISO 15223-1, it’s important to recognize that the recent amendment is not just an optional update but a necessary step to ensure ongoing compliance and relevance.
BS EN ISO 15223-1:2021+A1:2025 supersedes the original version, meaning that for regulatory declarations of conformity, the updated version is now required. Without this amendment, your products might fall out of compliance with critical regulations, particularly within the European Union.
Moreover, the changes introduced in the amendment reflect a broader move towards global standardization and efficiency in communication. By adopting the amended version, you ensure that your products remain competitive and compliant in a rapidly evolving market.
Don’t risk non-compliance or outdated practices. Purchase BS EN ISO 15223-1:2021+A1:2025 today and ensure that your medical devices meet the latest regulatory requirements, enhance safety and remain competitive in global markets.